Sugi Predict

Sugi Predict / Compounds / SCHEMBL1816740

SCHEMBL1816740

SCHEMBL1816740

Cc1ccc(C(=O)O)c(F)c1I

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KDM4E B2RXH2 2/20 0.41
▸ ASPH Q12797 1/20 0.41
▸ KDM8 Q8N371 1/20 0.41
▸ HAAO P46952 1/20 0.41
▸ CYP1A2 P05177 1/20 0.41
▸ HPGD P15428 2/20 0.40
▸ CLCN2 P51788 2/20 0.40
▸ ADRA2A P08913 1/20 0.40
▸ ALDH1A1 P00352 2/20 0.39
▸ HSD17B10 Q99714 1/20 0.39
▸ HTT P42858 1/20 0.39
▸ NOTUM Q6P988 1/20 0.39
▸ MCL1 Q07820 1/20 0.38
▸ RXRA P19793 1/20 0.38
▸ RXRB P28702 1/20 0.38
▸ MAP2K2 P36507 1/20 0.37
▸ MAP2K1 Q02750 1/20 0.37
▸ GABRP O00591 1/20 0.37
▸ GABRD O14764 1/20 0.37
▸ GABRA1 P14867 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16277449 0.86 HPGD (0.42) KDM4EASPHKDM8HAAOCYP1A2
SCHEMBL489533 0.83 HPGD (0.55) KDM4EASPHKDM8HAAOCYP1A2
SCHEMBL1918827 0.81 SOS1 (0.44) KDM4ECYP1A2HPGDALDH1A1HSD17B10
SCHEMBL7368860 0.81 MAP2K1 (0.45) KDM4EASPHKDM8CYP1A2HPGD
SCHEMBL10662412 0.81 KDM4E (0.42) KDM4EASPHKDM8HAAOCYP1A2
SCHEMBL27292205 0.79 KDM4E (0.46) KDM4EASPHKDM8HAAOCYP1A2
SCHEMBL1936626 0.78 CYP1A2 (0.44) KDM4EHAAOCYP1A2HPGDALDH1A1
SCHEMBL1671271 0.78 KDM4E (0.40) KDM4EASPHKDM8HAAOCYP1A2
SCHEMBL5737114 0.78 KDM4E (0.40) KDM4EASPHKDM8HAAOCYP1A2
SCHEMBL11775719 0.78 KDM4E (0.40) KDM4EASPHKDM8HAAOCYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 120 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250122226-A1 GLUCOSE-SENSITIVE ALBUMIN-BINDING DERIVATIVES NOVO NORDISK AS (DK) 2025-04-17 — — US disclosed
US-12227528-B2 Glucose-sensitive albumin-binding derivatives NOVO NORDISK A/S (DK) 2025-02-18 — — US disclosed
CN-117624207-A Glucose-sensitive albumin binding derivatives 诺和诺德股份有限公司 2024-03-01 — — CN disclosed
CN-111315751-B Glucose-sensitive albumin binding derivatives 诺和诺德股份有限公司 2023-12-12 — — CN disclosed
US-20230331745-A1 GLUCOSE-SENSITIVE ALBUMIN-BINDING DERIVATIVES NOVO NORDISK AS (DK) 2023-10-19 — — US disclosed
US-20230331745-A1 GLUCOSE-SENSITIVE ALBUMIN-BINDING DERIVATIVES NOVO NORDISK AS (DK) 2023-10-19 — — US disclosed
US-20230331745-A1 GLUCOSE-SENSITIVE ALBUMIN-BINDING DERIVATIVES NOVO NORDISK AS (DK) 2023-10-19 — — US disclosed
US-11767332-B2 Glucose-sensitive albumin-binding derivatives NOVO NORDISK A/S (DK) 2023-09-26 — — US disclosed
US-11767332-B2 Glucose-sensitive albumin-binding derivatives NOVO NORDISK A/S (DK) 2023-09-26 — — US disclosed
US-11767332-B2 Glucose-sensitive albumin-binding derivatives NOVO NORDISK A/S (DK) 2023-09-26 — — US disclosed
EP-1836174-A2 ARYL NITROGEN-CONTAINING BICYCLIC COMPOUNDS AND THEIR USE AS KINASE INHIBITORS AMGEN INC. (US) 2007-09-26 — — EP disclosed
US-20070185324-A1 Nitrogen-containing bicyclic heteroaryl compounds and methods of use AMGEN INC. 2007-08-09 — — US disclosed
US-20070185324-A1 Nitrogen-containing bicyclic heteroaryl compounds and methods of use AMGEN INC. 2007-08-09 — — US disclosed
WO-2007076092-A2 NITROGEN- CONTAINING BICYCLIC HETROARYL COMPOUNDS FOR THE TREATMENT OF RAF PROTEIN KINASE-MEDIATED DISEASES AMGEN INC. (US) 2007-07-05 — — WO disclosed
US-20070054916-A1 Aryl nitrogen-containing bicyclic compounds and methods of use AMGEN INC. 2007-03-08 — — US disclosed
US-20070054916-A1 Aryl nitrogen-containing bicyclic compounds and methods of use AMGEN INC. 2007-03-08 — — US disclosed
US-20070054916-A1 Aryl nitrogen-containing bicyclic compounds and methods of use AMGEN INC. 2007-03-08 — — US disclosed
WO-2006094187-A2 PHTHALAZINE, AZA- AND DIAZA-PHTHALAZINE COMPOUNDS AND METHODS OF USE AMGEN INC (US) 2006-09-08 — — WO disclosed
US-20060199817-A1 Phthalazine, aza- and diaza-phthalazine compounds and methods of use AMGEN INC. (US) 2006-09-07 — — US disclosed
WO-2006039718-A2 ARYL NITROGEN-CONTAINING BICYCLIC COMPOUNDS AND THEIR USE AS KINASE INHIBITORS AMGEN INC (US) 2006-04-13 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060199817-A1 Phthalazine, aza- and diaza-phthalazine compounds and methods of use DAPK2, CDK2, DAPK1 KDM4E 929/4885ASPH 2536/4885KDM8 437/4885
US-20070185324-A1 Nitrogen-containing bicyclic heteroaryl compounds and methods of use BRAF, NRAS, RAF1 KDM4E 1653/4885ASPH 3040/4885KDM8 1349/4885
US-12227528-B2 Glucose-sensitive albumin-binding derivatives ALB, DBI, FABP4 KDM4E 3966/4885ASPH 1685/4885KDM8 4439/4885
US-20230331745-A1 GLUCOSE-SENSITIVE ALBUMIN-BINDING DERIVATIVES ALB, DBI, FABP4 KDM4E 3966/4885ASPH 1685/4885KDM8 4439/4885
US-11767332-B2 Glucose-sensitive albumin-binding derivatives ALB, DBI, FABP4 KDM4E 3966/4885ASPH 1685/4885KDM8 4439/4885
US-20250122226-A1 GLUCOSE-SENSITIVE ALBUMIN-BINDING DERIVATIVES ALB, DBI, FABP4 KDM4E 3966/4885ASPH 1685/4885KDM8 4439/4885
US-20070054916-A1 Aryl nitrogen-containing bicyclic compounds and methods of use MAP3K1, MAP3K5, MAP3K2 KDM4E 1444/4885ASPH 1955/4885KDM8 884/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.